United Therapeutics has once again received a rejection from the FDA for its oral Remodulin for pulmonary arterial hypertension. In this video, Motley Fool health-care analyst David Williamson tells investors why this resubmission may have been too soon, what the company would need to do before the next resubmission to have a chance at approval, and who the hidden losers are in this rejection.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report " 3 Stocks That Will Help You Retire Rich " names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article United Therapeutics Can't Stop Getting Rejected originally appeared on Fool.com.David Williamson owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.